• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

    7/1/25 6:30:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FHTX alert in real time by email

    Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system

    The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering

    CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous product pipeline that is adaptive and responsive to variable climate conditions and capable of generating new solutions at a fraction of the time and cost associated with conventional agriculture approaches. Flagship has initially committed $50 million to Terrana to scale operations and develop its first products in crop protection and yield.

    Terrana Biosciences is an RNA-based platform company for agriculture.

    "At Flagship Pioneering, we build groundbreaking platforms that address the world's most pressing challenges. With Terrana, we are bringing an entirely new dimension of innovation to agriculture through similar RNA technology that we pioneered in human health," said Noubar Afeyan, Ph.D., Co-Founder of Terrana, Founder and CEO of Flagship Pioneering. "This approach will empower farmers with precise, adaptive solutions to combat threats to crops in fields and orchards and enhance resiliency, sustainability, and productivity in the global food system."

    Trees and crops naturally use a vast ecosystem of self-replicating RNAs to influence trait expression. These native RNAs are abundant, diverse, and are already part of the plant's own biology, functioning like a native language that helps to communicate traits like growth, stress response, and development. Using advanced AI and computational models, Terrana has assembled a vast library of RNAs and built a design system that enables efficient assembly of novel functional crop traits, generated with unprecedented precision, versatility and speed. The platform has already created three novel technology classes, demonstrated proof of concept in tomatoes, corn, and soy, and generated a pipeline of 15+ potential products in specialty and row crops.

    Tools developed using Terrana's platform will enable farmers to fight and prevent disease and pests, adapt quickly to climatic conditions, and maintain soil health. Terrana's solutions are fine-tuned for amplification, mobility in plants, stability in different environments, and heritability across plant generations. Terrana's product candidates also avoid the trade-offs of existing conventional approaches, which often can be applied only at a specific time in the plant's life cycle and come with negative environmental impacts.

    "RNA-based technology has delivered lifesaving advancements in human health. We are now applying this same approach to reimagine what's possible for agriculture," said Ignacio Martinez, Co-Founder and Executive Chairman of Terrana and General Partner at Flagship Pioneering. "Using the language of nature, we can give plants new instructions, yielding adaptable solutions rooted directly in the plant's natural physiology. Our approach opens a new world of possibilities in annual and perennial crops for the benefit of farmers, people and the planet."

    "Today, farmers make many important and costly decisions about seeds, fertilizers and crop protection before the crop year even begins, requiring them to rely on projections and historical trends from prior growing seasons rather than responding to real-time conditions on the ground," said Ryan Rapp, Co-Founder and CEO of Terrana Biosciences and Origination Partner at Flagship. "What's more, the increased pace of climate fluctuations and disease threats far exceeds today's slow and expensive R&D processes, leaving farmers all too often behind the curve. Terrana's ability to unlock all aspects of seed and crop traits in plants enables an entirely new set of agile solutions that can be applied at any time in the growing season, from seed to postharvest. In an increasingly unpredictable environment – from wildly fluctuating global markets to extreme weather events to fast-moving pest and disease pressures – farmers need these new tools to enable timely, efficient, nimble and, critically, cost-saving decision making."

    In addition to Rapp, Terrana's leadership team includes Matthew Lingard, Chief Technology Officer of Terrana and Senior Principal at Flagship, Folashade Sabitu, Head of Regulatory and Ramtin Ahmadi, Vice President of Strategy and Operations. Terrana also benefits from guidance from a board of directors that includes Martinez, longtime leader in global agriculture Hugh Grant, Invaio's CEO and Flagship CEO-Partner Amy O'Shea, and Flagship's Chair of Asia Pacific and Strategic Advisor, André Andonian. To learn more about Terrana, visit www.terranabio.com.

    About Terrana Biosciences

    Terrana Biosciences combines RNA technology with advanced computational biology to deliver sustainable solutions for modern agriculture. Through its proprietary platform, the company is pioneering new technology classes and generatively designing versatile RNA-based products for every aspect of plant health, from seed to stem. Founded by Flagship Pioneering in 2021, Terrana is led by an experienced team, including RNA and plant pathology experts.

    About Flagship Pioneering

    Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Tessera Therapeutics and Valo Health.

    Media Contact: [email protected]

    (PRNewsfoto/Flagship Pioneering)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-terrana-biosciences-to-deliver-adaptive-targeted-agricultural-solutions-through-a-novel-rna-technology-platform-302494682.html

    SOURCE Flagship Pioneering

    Get the next $FHTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX
    $MRNA
    $SANA

    CompanyDatePrice TargetRatingAnalyst
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Foghorn Therapeutics Inc.
    $FHTX
    12/18/2025$11.00Buy
    BTIG Research
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Foghorn Therapeutics Inc.
    $FHTX
    11/7/2025$12.00Buy
    Guggenheim
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    Foghorn Therapeutics Inc.
    $FHTX
    9/17/2025$10.00Buy
    B. Riley Securities
    More analyst ratings

    $FHTX
    $MRNA
    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Patel Dhavalkumar Dhirajlal

    3 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/27/26 4:15:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Harr Steve covered exercise/tax liability with 24,345 shares and converted options into 91,666 shares, increasing direct ownership by 0.85% to 7,944,251 units (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/10/26 4:16:12 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wyrick Susan D. converted options into 13,666 shares and covered exercise/tax liability with 4,387 shares, increasing direct ownership by 5% to 196,196 units (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/10/26 4:15:55 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Foghorn Therapeutics with a new price target

    Jefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    2/17/26 7:49:23 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

    FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL) Completed a $50 million registered direct financing in January 2026 Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of the January 2026 financing, the company has cash runway into the firs

    3/11/26 4:09:46 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

    Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression Made significant progress with SC451 across manufa

    3/3/26 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. TD Cowen 46th Annual Health Care Conference Presentation: Tuesday, March 3, 2026, at 11:10 a.m. EDTPresenter: Adri

    2/24/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $MRNA
    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.

    SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)

    3/27/26 10:51:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Foghorn Therapeutics Inc.

    S-8 - Foghorn Therapeutics Inc. (0001822462) (Filer)

    3/26/26 4:03:20 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Moderna Inc.

    DEF 14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:31:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. "I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, Pres

    2/23/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $MRNA
    $SANA
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

    8/6/25 7:00:00 AM ET
    $MCRB
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

    First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

    1/7/25 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

    Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

    11/7/24 6:30:00 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care